The global vascular graft market size is estimated to grow at a CAGR of 6.2% from 2024 to 2029. Thus, the global vascular graft market is developing at a rapid pace.
Vascular grafts are used for hemodialysis vascular access and endovascular aneurysm & thoracic aneurysm repair. A vascular graft is a surgery process to redirect blood from an area of normal blood flow to another relatively normal area. Various vascular grafts are based on the indication and raw material used for the graft to suit host tissue.
Across the globe, around 2 million people are suffering from ESRD, as per the University of California. In regions such as the US, Taiwan, Belgium, Mexico, and Japan, nearly 650,000 people suffer from ESRD. So, there is a high prevalence of ESRD. Growing disposable income in urban areas is also greatly influencing the growth rate of the market. There is an increase in the geriatric population worldwide, creating a positive impact on the market. The prevalence of a sedentary lifestyle in which there are smoking and drinking has boosted the market growth. The rise in diabetes cases has also increased the number of patients requiring the vascular shaft, contributing more to the growth rate. Cardiovascular diseases are a significant cause of death worldwide, and this vascular graft is used to treat such diseases.
The vascular graft market is providing opportunities for emerging markets. Emerging markets like Singapore, China, Japan, and Australia are growing significant opportunities for players to operate in the vascular graft market. The market is expected to experience substantial growth in forthcoming years due to owning lenient regulatory policies and increasing the burden of aneurysms. In addition, to expand geographic reach, significant players are prompting an emerging market. These are opportunities provided for the vascular graft market.
The major restraint in the vascular graft market is the failure of the product and recalls. For many years, offered products are recalling by companies due to malfunctions or other issues. End-user perception of the safety of grafts can be hurt by market development. It can affect the adoption of the treatment process, which is also hindering the market's growth rate. The other significant restraint of the market is to make the vascular graft procedure less costly and more affordable to people. The low reimbursements for people have also hindered market growth and are expected to impact the future negatively. The development of healthcare facilities is not at the same level everywhere, and the procedure requires high-quality facilities, thus negatively impacting the market growth. Complications associated with prosthetic grafts are also a major restrain to the market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product, Raw Materials, End User, Application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Endologix Inc., LeMaitre Vascular, Inc., MAQUET Holding B.V.B. Braun Melsungen AG, & Co. KG, Medtronic plc, C. R. Bard, Inc., Cardinal Health Inc., Cook Medical Inc., Terumo Corporation, and W. L. Gore & Associates, Inc. |
Based on the product, the Endovascular stent grafts segment accounted for the largest share owing to the rise in the adoption of endovascular aneurysm repair surgeries, the increment of preference for minimally invasive surgical processes over open surgeries, and the growth of the geriatric population.
Based on raw material, polyester-based grafts dominate the market due to the easy availability of raw material, high tensile strength, and durability. The leadership of this segment is attributed to the growth in the easy availability of raw materials, high tensile strength, and more durability than other material grafts. In addition, the increasing cases and rising awareness have also boosted market growth.
Polytetrafluroethane is expected to grow fastest among all other segments during the forecast period. PTFE is fabricated with a technically advanced architecture that minimizes blood loss and provides maximum protection against delamination. The PTFE material is also used for peripheral bypasses and extra anatomical procedures. In addition, the increase in the number of cases of cardiovascular diseases will ensure the growth of the market.
The hospital segment is expected to grow with the highest growth rate during the forecast period based on the end-user. The availability of better-quality healthcare infrastructure and facilities has positively impacted this sub-segment. In addition, the rise of minimally invasive procedures at hospitals has also accelerated market growth, and the favorable reimbursement scenario in most developed countries has allowed more people to undertake these surgeries.
Ambulatory surgical centers will also grow reasonably in the future, mainly due to rising CVD cases and advancements in healthcare facilities.
Based on the application, the cardiac aneurysms segment led the market in 2023 and is expected to grow at a reasonable rate due to factors such as the high prevalence of high blood pressure and the advent of advanced tissue-engineered grafts for pediatric congenital heart surgeries. In addition, the development in healthcare facilities will help this sub-segment to grow.
The increasing geriatric population and unhealthy lifestyle habits, such as alcohol consumption and smoking, are anticipated to contribute to the rising growth rate during the forecast period.
Geographically, the North American vascular graft treatment market is expected to have the largest market share due to factors like the increasing geriatric population suffering from cardiovascular diseases, diabetes, and end-stage renal diseases. Expecting that North America will maintain its position as it has a prevalence of diabetes, cardiovascular diseases, and chronic kidney diseases. Moreover, advanced technology is also available, and reimbursement coverage is a driving factor in the vascular graft market. The increase in diabetes cases, cardiovascular diseases, and kidney problems have boosted this region's growth.
The European vascular graft treatment market is expected to hike rapidly during the forecast period. Europe is also attributing the highest compound annual growth rate as it increases the numerous biomaterials research projects. A partnership was made by the European Union with a medical organization to have funds. Increment in incidences of cardiovascular diseases and growth of accepting prosthetic graft implantation in Europe region. The main reason for this growth is the increase in the geriatric population, healthcare facilities' advancement, and better healthcare quality. The rising initiatives will accelerate the market further.
During the forecast period, the Asia-Pacific vascular graft treatment market is the second-largest regional market in the vascular graft market, with a compound annual growth rate of 8.1%. Improvement of healthcare infrastructure and incidences of cardiovascular diseases and diabetics are the attributing factors in the Asia-Pacific region. Moreover, a rapid increase in epidemiological transition resulted in many premature deaths, expected as a booster demand for minimally invasive grafting procedures during the forecast period. In addition, the implementation of extensive R&D for new product development is due to a rise in heart failure cases.
Some of the key companies playing a dominant role in the Global Vascular Graft Market profiled in this report are Endologix Inc., LeMaitre Vascular, Inc., MAQUET Holding B.V.B., Braun Melsungen AG, & Co. KG, Medtronic plc, C. R. Bard, Inc., Cardinal Health Inc., Cook Medical Inc., Terumo Corporation and W. L. Gore & Associates, Inc.
By Product
By Raw Material
By End User
By Application
By Region
Frequently Asked Questions
The risk of graft failure, the need for more effective and long-lasting grafts, and the high cost of vascular graft procedures are some of the major challenges to the vascular graft market.
Endologix Inc., LeMaitre Vascular, Inc., MAQUET Holding B.V.B., Braun Melsungen AG, & Co. KG, Medtronic plc, C. R. Bard, Inc., Cardinal Health Inc., Cook Medical Inc., Terumo Corporation and W. L. Gore & Associates, Inc. are some of the major players in the vascular graft market.
The use of tissue engineering to create more biocompatible and long-lasting grafts, the development of nanotechnology-based vascular grafts, and the use of 3D printing to create patient-specific vascular grafts are some of the potential future developments in the vascular graft market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region